Grifols Wins FDA Approval for Fibrin Sealant
Grifols won the FDA’s approval for its Fibrin Sealant for surgical use in adults, the company announced in a Securities and Exchange Commission filing.
The device is composed of the plasma proteins fibrinogen and human thrombin.
Grifols said the U.S. approval will allow it to expand its range of plasma-derived products. The sealant will be manufactured at the Grifols facility in Barcelona, Spain.